12 research outputs found
Rough Waters for the Ratings Companies: Should the Securities Ratings Companies Be Held Liable for Investor Reliance in the Wake of the Real Estate Meltdown of 2007-2008?
- Author
- &
- &
- &
- &
- &
- &
- &
- &
- &
- A Brooke Overby
- Denzel Causey
- E G See
- E G See
- Id
- Id
- Id
- Id
- Id
- Id
- Id
- Id
- Joint Release
- Kathleen C Engel &
- Kathleen C Engel &
- Kathleen M Howley
- Kenneth Temkin
- Kristofor William Nelson
- Micheal H Schill
- Overby
- Overby
- Overby
- Overby
- Overby
- Schill
- Schill
- Schill
- Schill
- Securities
- See Id
- See Rosenblum
- See Rosenblum
- Sept Sirri
- Sirri
- Sirri
- Worley V
- Publication venue
- 'Elsevier BV'
- Publication date
- 01/01/2009
- Field of study
Obesity and Prolonged Pregnancy
- Author
- Publication venue
- 'Elsevier BV'
- Publication date
- 01/01/2013
- Field of study
How much do superbugs cost Australian hospitals? An evidence-based open-access tool
- Author
- Publication venue
- 'Elsevier BV'
- Publication date
- Field of study
Hunger and Equity in an Era of Genetic Engineering
- Author
- Am
- Andrew Pollack
- Bruce Stutz
- Carey Gillam
- Charles C Mann
- Colleen Scherer
- Dan Charles
- Dan See Also
- David Quist
- David Rotman
- Diana L Letter From
- E
- E G See
- E G See
- Emily Waltz
- Emma J Rosi-Marshall
- George Monbiot
- George Monbiot
- Glenn Davis Stone
- Harald Witt
- Henry I Miller
- Hilbeck
- Hugh Grant
- Hugh Turral
- Id
- Id
- Joint Statement
- Jorge Fernandez-Cornejo Et Al
- Mann
- Martin Enserink
- Monbiot
- Nat&apos
- Nat&apos
- Nathanael Johnson
- Nina V Fedoroff
- Oliver Nieburg
- Philip Clarke
- Press Release
- Press Release
- Rebecca M. Bratspies
- Supra Johnson
- Tom Meersman
- Usda Extension
- Waltz
- Waltz
- Publication venue
- 'Elsevier BV'
- Publication date
- 01/01/2017
- Field of study
Secondary liability in the post Napster era: Ethical observations on MGM v. Grokster
- Author
- Amici Curiae Brief
- Amici Curiae Brief
- Appellants Opening Brief
- Bayertz K.
- Benkler Y
- Cope J.
- Dogan S.
- Fagin M.
- Grisez G.
- Grossman L.
- Ikezoye Declaration
- In
- Kraakman R.
- Lessig L.
- Lichtman D.
- Ligouri
- Metro-Goldwyn-Mayer
- Metro-Goldwyn-Mayer
- Petition
- Plaintiffs' Joint Excerpts
- Press Release
- Richard A. Spinello
- Sony Corp of America v.
- Statement
- Woellert L.
- Zeller T.
- Publication venue
- 'Emerald'
- Publication date
- Field of study
In Whose Interest? The UN's Strategic Rapprochement with Business in the Sustainable Development Agenda
- Author
- ACORD
- Barnett M. N.
- Bruno K.
- Bull B.
- Bull B.
- Bäckstrand K.
- Cammack P.
- Emmerij L.
- European Commission
- FOEI
- High-Level Panel of Eminent Persons on the post-2015 Development Agenda (HLP)
- ICAI
- Jolly R.
- Kwakkenbos J.
- Leisinger K.
- Lou Pingeot
- McKeon N.
- Muchhala B.
- Reinalda B.
- Ruggie J. G.
- Sagafi-Nejad T.
- SDSN
- Social Watch
- Tesner S.
- Thérien J. P.
- Thérien J. P.
- UN
- UN General Assembly
- UN General Assembly
- UN Global Compact
- UN Global Compact and WBCSD
- UN Joint Inspection Unit
- UN Press Release
- Unilever
- Utting P.
- World Economic Forum
- Zammit A.
- Publication venue
- 'Informa UK Limited'
- Publication date
- Field of study
Debate on the Chernobyl Disaster
- Author
- Abrosimov AIu
- Baldwin J
- Bandazhevskaya GS
- Demidchik YE
- Furmanchuk AW
- Hatch M
- Havenaar JM
- Ivanov VK
- Jargin SV
- Jargin SV
- Jargin SV
- Jargin SV
- Jargin SV
- Jargin SV
- Jargin SV
- Jargin SV
- Jargin SV
- Jargin SV
- Jargin SV
- Jargin SV
- Jargin SV
- Kabuto M
- Karam PA
- Kesminiene A
- Kholodova EA
- McGeoghegan D
- Mezei G
- Mould RF
- Nesterenko VB
- Nikiforov Y
- Parkin DM
- Parshkov EM
- Prysyazhnyuk AYe
- Romanenko A
- Romanenko A
- Romanenko A
- Romanenko AM
- Semenov AN
- Sergei V. Jargin
- Smith J
- Stsjazhko VA
- Tronko MD
- Watanabe T
- WHO/IAEA/UNDP Joint News Release
- Williams D
- Williams ED
- Yablokov AV
- Publication venue
- 'SAGE Publications'
- Publication date
- Field of study
Micronutrient status of Palestinian school children following salt and flour fortification: a cross-sectional study
- Author
- A Abudayya
- A Khader
- A Lindsay
- AO Musaiger
- B de Benoist
- C Best
- I Elmadfa
- International Zinc Nutrition Consultative Group
- Joint press release by the Palestinian Central Bureau of Statistics (PCBS) the Food and Agriculture Organization (FAO), the United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA) and the World Food Programme (WFP)
- K Muhsen
- M Brown
- Ministry of Education and Higher Education
- Ministry of Education and Higher Education
- MM Sirdah
- Palestinian Central Bureau of Statistics
- Palestinian Central Bureau of Statistics
- Palestinian Central Bureau of Statistics
- Palestinian Central Bureau of Statistics
- RE Black
- RL Bailey
- S Adu-Afarwuah
- S Massad
- United Nations Children’s Fund
- World Health Organization Regional Office for the Meditarrean Region
- Publication venue
- 'Springer Science and Business Media LLC'
- Publication date
- Field of study
Abuse-deterrent Opioid Formulations
- Author
- Institute for Clinical and Economic Review: Abuse-deterrent formulations of opioids: Effectiveness and value
- Multistate Insider: States have stalled on potential opioid abuse solution: Deterrent formulation drugs
- Office of National Drug Control Policy USA: National Drug Control Strategy
- Office of National Drug Control Policy USA: National Heroin Task Force final report and recommendations
- Pfizer Inc.: Embeda® (morphine sulfate and naltrexone HCl)
- Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality: Results 2015 National Survey on Drug Use and Health: Detailed tables
- U.S. Food and Drug Administration: Abuse-deterrent opioids—evaluation and labeling. Guidance for industry
- U.S. Food and Drug Administration: Briefing document: Joint meeting of Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee
- U.S. Food and Drug Administration: Center for Drug Evaluation and Research: Data and methods for evaluating the impact of opioid formulations with properties designed to deter abuse in the postmarket setting
- U.S. Food and Drug Administration: Determination that the OxyContin (oxycodone hydrochloride) products covered by New Drug Application 20–553 were withdrawn from sale for reasons of safety or effectiveness
- U.S. Food and Drug Administration: FDA actions on OxyContin products
- U.S. Food and Drug Administration: FDA approves Targiniq ER with abuse-deterrent properties
- U.S. Food and Drug Administration: FDA requests removal of Opana ER for risks related to abuse
- U.S. Food and Drug Administration: Opioids action plan
- U.S. Food and Drug Administration: Postmarketing safety issues related to reformulated Opana ER®
- U.S. Food and Drug Administration: Sponsor briefing document: Arymo™ ER (morphine sulfate) extended-release tablets
- U.S. Food and Drug Administration: Summary review for regulatory action: Hysingla® ER
- Publication venue
- 'Ovid Technologies (Wolters Kluwer Health)'
- Publication date
- Field of study